Japan Experts, Extraordinary Performance, Astris Advisory Japan

Astris Advisory Japan

Japan Experts, Extraordinary Performance

Our Corporate Advisory service is designed to give clients access to a wider range of investors. These include Japan specialists as well as global investors. The goal is to help achieve a fair equity valuation.

Equity Bottom-Up

<ul><li>AS ONE flexed its procurement muscles and kept plastic consumables on the shelf through a geopolitics-driven shortage, which allowed them to capture a rapid ramp in customer demand, improving engagement with existing customers and drawing in new customers.</li><li>Higher input costs were passed through to customers in a timely manner and demonstrating gross margin durability, which we believe matters more than the record earnings.</li><li>We note particular strength in the Industrial segment, where AS ONE benefited from semiconductor sector demand for cleanroom consumables. </li></ul>

AS ONE flexed its procurement muscles and kept plastic consumables on the shelf through a geopolitics-driven shortage, which allowed them to capture a rapid ramp in customer demand, improving engagement with existing customers and drawing in new customers.Higher input costs were passed through to customers in a timely manner and demonstrating gross margin durability, which we believe matters more than the record earnings.We note particular strength in the Industrial segment, where AS ONE benefited from semiconductor sector demand for cleanroom consumables. 

AS ONE (7476 JP) - Resilient Supply Chain, Durable Margins

<ul><li>FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the operating leverage in its model.</li><li>The FY3/27 financial guidance points to a year of growth investments, which should translate to profitability improvement in future years.</li><li>We note that AS ONE has maintained a strong track record of cost discipline, which makes us believe the elevated SG&amp;A spend in FY3/27 is expected to generate meaningful returns. </li></ul>

FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the operating leverage in its model.The FY3/27 financial guidance points to a year of growth investments, which should translate to profitability improvement in future years.We note that AS ONE has maintained a strong track record of cost discipline, which makes us believe the elevated SG&amp;A spend in FY3/27 is expected to generate meaningful returns. 

As One (7476 Jp) - Setting Conservative Expectations for FY3/27

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>AS ONE is a dominant wholesaler of laboratory and scientific equipment in Japan, leveraging a catalog and e-commerce model for efficient distribution and high profitability.</li>
  <li>The company is well-positioned to benefit from steady growth in Japan's laboratory equipment market, driven by an aging population, increased R&amp;D in life sciences, and a governmental push for new drug approvals.</li>
  <li>Despite consistent revenue growth and a strong market position, the company faces challenges from a declining market cap trend over the last three years and potential margin pressures from investments in logistics and e-commerce infrastructure.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  AS ONE is a dominant wholesaler of laboratory and scientific equipment in Japan, leveraging a catalog and e-commerce model for efficient distribution and high profitability.
  The company is well-positioned to benefit from steady growth in Japan's laboratory equipment market, driven by an aging population, increased R&amp;D in life sciences, and a governmental push for new drug approvals.
  Despite consistent revenue growth and a strong market position, the company faces challenges from a declining market cap trend over the last three years and potential margin pressures from investments in logistics and e-commerce infrastructure.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: AS ONE Corporation (7476 JP) - May 2026

<ul><li>Early signs of inflection as macro clouds clear – AS ONE's Q1-3 results demonstrated strong operational execution with operating profit (+12.4% YoY) significantly outpacing revenue growth (+5.1% YoY), reflecting margin expansion and cost discipline.</li><li>Looking ahead, macroeconomic headwinds are fading as Japan-U.S. tariff uncertainty resolves and corporate earnings improve, while the Takaichi administration's anticipated fiscal stimulus measures are expected to benefit AS ONE's core customer base (universities, research institutions, and medical facilities), positioning the Company for reacceleration of growth in FY3/27.</li><li>With the ¥1bn share buyback program completed ahead of schedule, AS ONE maintains the flexibility to return additional capital to shareholders if M&amp;A opportunities do not meet return hurdles.</li></ul>

Early signs of inflection as macro clouds clear – AS ONE's Q1-3 results demonstrated strong operational execution with operating profit (+12.4% YoY) significantly outpacing revenue growth (+5.1% YoY), reflecting margin expansion and cost discipline.Looking ahead, macroeconomic headwinds are fading as Japan-U.S. tariff uncertainty resolves and corporate earnings improve, while the Takaichi administration's anticipated fiscal stimulus measures are expected to benefit AS ONE's core customer base (universities, research institutions, and medical facilities), positioning the Company for reacceleration of growth in FY3/27.With the ¥1bn share buyback program completed ahead of schedule, AS ONE maintains the flexibility to return additional capital to shareholders if M&amp;A opportunities do not meet return hurdles.

AS ONE (7476 JP) - Positioning for Growth Reacceleration in FY3/27

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Shanghai Henlius Biotech announced that PMDA of Japan approved phase 2/3 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) for advanced squamous non-small cell lung cancer (NSCLC).</li>
<li>Simcere Pharmaceutical announced that, SIM0613 for Injection, an antibody-drug conjugate, received the clinical trial approval in China, and is intended for commencing the clinical trial for advanced solid tumors.</li>
<li>Olympus has signed an exclusive global distribution agreement with EndoRobotics. Under this agreement, robot-assisted technologies manufactured by EndoRobotics will be distributed globally by Olympus exclusively.</li>
</ul>


Shanghai Henlius Biotech announced that PMDA of Japan approved phase 2/3 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) for advanced squamous non-small cell lung cancer (NSCLC).
Simcere Pharmaceutical announced that, SIM0613 for Injection, an antibody-drug conjugate, received the clinical trial approval in China, and is intended for commencing the clinical trial for advanced solid tumors.
Olympus has signed an exclusive global distribution agreement with EndoRobotics. Under this agreement, robot-assisted technologies manufactured by EndoRobotics will be distributed globally by Olympus exclusively.


APAC Healthcare Weekly (May 10) – Henlius Bio, Simcere, Olympus, Daewoong Pharma

Japan

AS ONE CORPORATION wholesales laboratory equipment, scientific equipment, and related products.  The Company sells its products through catalogs and provides quick delivery by using the on-line ordering system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AS ONE Corporation (7476 JP)

AS ONE (7476 JP) - Resilient Supply Chain, Durable Margins

We note particular strength in the Industrial segment, where AS ONE benefited from semiconductor sector demand for cleanroom consumables.

Astris Advisory Japan

As One (7476 Jp) - Setting Conservative Expectations for FY3/27

FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the...

Astris Advisory Japan

Primer: AS ONE Corporation (7476 JP) - May 2026

AS ONE is a dominant wholesaler of laboratory and scientific equipment in Japan, leveraging a catalog and e-commerce model for efficient...

αSK Primers

AS ONE (7476 JP) - Positioning for Growth Reacceleration in FY3/27

AS ONE's Q1-3 results demonstrated strong operational execution with operating profit (+12.4% YoY) significantly outpacing revenue growth (+5.1%...

Astris Advisory Japan

APAC Healthcare Weekly (May 10) – Henlius Bio, Simcere, Olympus, Daewoong Pharma

Henlius Bio and Simcere got trial approval for their respective ADC candidates in Japan and China, respectively. Olympus forges exclusive global...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)